- IntraLinks will Help to Meet the Pharmaceutical Industry's Objective to Move Towards Completely Paperless Clinical Trials
NEW YORK, May 12 /CNW/ - IntraLinks, the leading provider of critical information exchange solutions, today announced a partnership with SAFE-BioPharma, the non-profit association that created and manages the SAFE-BioPharma(R) digital identity and signature standard for the pharmaceutical and healthcare industries. IntraLinks users, which include the top 10 pharmaceutical, biotechnology and contract research organizations (CROs) worldwide, will now be able to use the SAFE-BioPharma digital identity for signing documents. They can increase clinical trial efficiency by signing paperwork with a SAFE credential that provides additional security and speed, eliminating printing of hard copy casebooks and other documents.
IntraLinks provides automated and secure document sharing solutions for the life sciences industry. Its SaaS-based platform already helps pharmaceutical and clinical and safety teams achieve greater efficiencies, improve regulatory compliance and reduce risk but providing an alternative to the "wet" signature will help to take this to the next level. Users will have the opportunity to securely upload and use their SAFE-BioPharma digital identities on the IntraLinks(R) platform, ensuring that their credentials are available anytime and anywhere via the Web. IntraLinks is also enabling documents signed with SAFE-BioPharma signatures to be stored and shared on its existing platform.
"Incorporating SAFE-BioPharma's digital identity and signature standard into IntraLinks' platform is very significant for our clients and the community who rely on IntraLinks to manage their clinical trial communication and document exchange," said Alison Shurell, VP, life sciences product marketing, IntraLinks. "In addition to already being able to securely upload, receive, review and distribute documents on IntraLinks, sponsors, CROs and investigators will soon be able to eliminate the need to print out or physically store the numerous documents that require signatures during a clinical trial. It was an easy choice for us to partner with SAFE-BioPharma because its digital signature standard is recognized in the life sciences industry for providing a secure, enforceable, and regulatory-compliant way to verify identities and apply digital signatures in electronic transactions."
"Our mission is to facilitate the transformation of the pharmaceutical and healthcare communities to a fully electronic business environment by 2015," said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma. "SAFE-BioPharma members welcome the incorporation of the community's digital identity and signature standard into the IntraLinks platform. This new capability will help life sciences professionals further simplify and manage compliance and security within a seamless paperless environment."
In addition to incorporating the digital signature into its platform, IntraLinks has joined the SAFE-BioPharma vendor partner community. Members already include companies such as Microsoft, IBM, Adobe and Citigroup.
IntraLinks is a leading global provider of Software-as-a-Service solutions for securely managing content, exchanging critical business information and collaborating within and among organizations. More than 1,000,000 professionals in industries including financial services, pharmaceutical, biotechnology, consumer, energy, industrial, legal, insurance, real estate and technology, as well as government agencies, have utilized IntraLinks' easy-to-use, cloud-based solutions. IntraLinks users can accelerate information-intensive business processes and workflows, meet regulatory and risk management requirements and collaborate with customers, partners and counterparties in a secure, auditable and compliant manner. IntraLinks counts 800 of the Fortune 1000 as users. For more information, visit http://www.intralinks.com or http://blog.intralinks.com. You can also follow IntraLinks on Twitter at http://twitter.com/intralinks and Facebook at http://www.facebook.com/IntraLinks.
About SAFE-BioPharma Association (http://www.safe-biopharma.org)
SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma(R) digital identity and signature standard for the pharmaceutical and healthcare industries. It provides users with a secure, enforceable, and regulatory compliant way to verify identities of parties involved in electronic transactions and to apply digital signatures to electronic documents.
The Association's members include:
- Abbott (NYSE: ABT)
- Amarin Corp. (NASDAQ: AMRN),
- Amgen (NASDAQ: AMGN)
- AstraZeneca (NYSE: AZN)
- Bristol-Myers Squibb (NYSE: BMY)
- GlaxoSmithKline (NYSE: GSK)
- Johnson & Johnson (NYSE: JNJ)
- Eli Lilly (NYSE: LLY)
- McDougall Scientific
- Merck (NYSE: MRK)
- MWB Consulting Limited
- National Notary Association
- Oxford Outcomes
- Pfizer (NYSE: PFE)
- Premier Inc.
- Sanofi-Aventis (NYSE: SNY).
- SNAP Diagnostics
SAFE-BioPharma(R) is a registered trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.
For further information: For further information: Radley Moss, email@example.com, (212) 543-7717